Skip to main content

Articles

FDA Approvals, In the News
FDA Approves Pembrolizumab plus Axitinib for Advanced Renal-Cell Carcinoma
Read More
Review Article, Dermatology, Original Research
The Challenge of Managing Atopic Dermatitis in the United States
Steven R. Feldman, MD, PhD; Linda S. Cox, MD; Lindsay C. Strowd, MD; Robert A. Gerber, PharmD, MA, MBA; Steven Faulkner, PharmD, MBA; Debra Sierka, PharmD; Timothy W. Smith, BA; Joseph C. Cappelleri, PhD; Mark E. Levenberg, DO
Stakeholder Perspective
Evolving Therapies for Atopic Dermatitis Will Create New Management Challenges
Gary M. Owens, MD
Read More
Original Research, Cardiometabolic Health
Can Academic Detailing Move the Needle for Patients with Diabetes in a State-Based Prescription Drug Benefit Program?
Dominick P. Trombetta, PharmD, BCPS, BCGP; Debra A. Heller, PhD, MPH
Read More
Perspectives
Pharmacy Integration
David B. Nash, MD, MBA
Read More
Original Research, Practice Management
The Economic Value of Customized versus Off-the-Shelf Knee Implants in Medicare Fee-for-Service Beneficiaries
Mary I. O’Connor, MD; Brittany E. Blau, MPH
Read More
FDA Approvals
Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation
Read More
FDA Approvals, In the News
April 16, 2019 – FDA Approvals, News & Updates
Read More
FDA Approvals
Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma
Read More
FDA Approvals
Lorbrena (Lorlatinib) Approved for the Treatment of Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
Read More
FDA Approvals
Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors
Read More
Page 54 of 244
Results 531 - 540 of 2436